Shiga toxin-producing E. coil (STEC) is an emerging infectious pathogen that causes in excess of 30,000 cases of disease per year in the United States. STEC, including E. coil O157:H7, is also the leading cause of acute renal failure, hemolytic uremic syndrome (HUS), in young children. No effective preventive modality or therapeutic intervention is currently available for this disease. This project is designed to more fully describe a """"""""window of opportunity"""""""" available for treatment and prevention of STEC-associated acute renal failure. In most cases, a three to nine day period of renal inflammation takes place between the appearance of bloody diarrhea and the onset of acute renal failure. It is believed that STEC virulence factors such as Shiga toxin (Stx2) and lipopolysaccharide (LPS) are the primary initiators of the renal disease. These factors elicit production of pro-inflammatory host cytokines and chemokines. This study utilizes a murine model to define the cytokines and chemokines involved and describe how these agents cause migration and accumulation of inflammatory cell types in the kidney. These cell types include neutrophils, monocytes/macrophages and platelets. Mice with mutated cytokine, chemokine, or adherence factor genes are to be employed to determine which of these factors are required in the disease process. In addition, adherence of these cell types to isolated endothelial cells under flow conditions is included to define the inflammatory action of Stx2 and LPS. Studies are also included to show how host cytokines and chemokines further sensitize endothelial cells to Stx2 by activation of intracellular signal transduction pathways. The goal of these studies is to reveal the opportunities available for effective application of therapeutic agents in STEC-associated renal disease.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BM-1 (05))
Program Officer
Schmitt, Clare K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Virginia
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Obrig, Tom G; Karpman, Diana (2012) Shiga toxin pathogenesis: kidney complications and renal failure. Curr Top Microbiol Immunol 357:105-36
Fujii, Jun; Naito, Mariko; Yutsudo, Takashi et al. (2012) Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice. Clin Vaccine Immunol 19:1932-7
Obata, Fumiko; Obrig, Tom (2010) Distribution of Gb(3) Immunoreactivity in the Mouse Central Nervous System. Toxins (Basel) 2:1997-2006
Obrig, Tom G (2010) Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease. Toxins (Basel) 2:2769-2794
Psotka, Mitchell A; Obata, Fumiko; Kolling, Glynis L et al. (2009) Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect Immun 77:959-69
Roche, James K; Stone, Matthew K; Gross, Lisa K et al. (2008) Post-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model. Lab Invest 88:1178-91
Obata, Fumiko; Tohyama, Koujiro; Bonev, Adrian D et al. (2008) Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J Infect Dis 198:1398-406
Roche, James K; Keepers, Tiffany R; Gross, Lisa K et al. (2007) CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation. Am J Pathol 170:526-37
Louise, C B; Obrig, T G (1994) Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro. Microvasc Res 47:377-87
Obrig, T G; Louise, C B; Moran, T P et al. (1993) Direct cytotoxic effects of hemorrhagic toxins from Crotalus ruber ruber and Crotalus atrox on human vascular endothelial cells, in vitro. Microvasc Res 46:412-6